September 26, 2016
In 2013 a former employee of the pharmaceutical company Novartis allegedly manipulated clinical data for blood pressure drug Diovan.
Concerns were first raised when it was discovered that an employee was involved in the university run heart studies after the drug Diovan came onto the market. The employee did not disclose his affiliation with the company in the published findings. Novartis is standing behind its claims for the effectiveness of Diovan but has implemented changes at its Japanese unit, including conducting an independent review of the way it conducts post-trial phase studies.
The former employee was awaiting charge by the Tokyo district prosecutor and the company was facing criminal charges in connection with his actions. The company said it would review the charges once it received official notification, and would co-operate with authorities.